Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets

v2.4.0.8
Consolidated Balance Sheets (USD $)
Feb. 28, 2014
Nov. 30, 2013
Current Assets    
Cash and cash equivalents $ 3,243,003 $ 3,925,156
Restricted cash 943,964 968,130
Marketable securities and other investments 99,595 37,910
Accounts receivable (net of allowance for doubtful accounts of $1,960,421 and $1,994,575, respectively ) 3,704,218 3,336,460
Note receivable    550,782
Prepaid expenses and other current assets 567,211 644,969
Total current assets 8,557,991 9,463,407
Property and Equipment-net 1,123,339 1,207,279
Other Assets    
Investment in Saneron CCEL Therapeutics, Inc. 684,000 684,000
Deposits and other assets, net 102,640 146,116
Total other assets 786,640 830,116
Total assets 10,467,970 11,500,802
Current Liabilities    
Accounts payable 1,426,001 1,194,825
Accrued expenses 1,086,817 1,800,811
Deferred revenue 6,162,594 6,814,797
Total current liabilities 8,675,412 9,810,433
Other Liabilities    
Deferred revenue, net of current portion 8,624,533 8,658,354
Long-term liability - revenue sharing agreements 2,300,000 2,300,000
Total other liabilities 10,924,533 10,958,354
Commitments and Contingencies (Note 7)      
Stockholders' Deficit    
Preferred stock ($.01 par value, 500,000 authorized and none issued)      
Common stock ($.01 par value, 20,000,000 authorized; 11,870,040 issued and 10,525,474 outstanding as of February 28, 2014 and 11,870,040 issued and 10,743,225 outstanding as of November 30, 2013) 118,700 118,700
Additional paid-in capital 27,456,151 27,265,340
Treasury stock, at cost (3,378,036) (2,926,123)
Accumulated deficit (33,328,790) (33,725,902)
Total stockholders' deficit (9,131,975) (9,267,985)
Total liabilities and stockholders' deficit $ 10,467,970 $ 11,500,802